tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Paradigm Biopharmaceuticals to Quote New Securities on ASX
Company AnnouncementsParadigm Biopharmaceuticals to Quote New Securities on ASX
19h ago
Paradigm Biopharmaceuticals Announces Extraordinary General Meeting
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Extraordinary General Meeting
4d ago
Paradigm Biopharmaceuticals Updates on Phase 3 iPPS Trial
PremiumCompany Announcements
Paradigm Biopharmaceuticals Updates on Phase 3 iPPS Trial
26d ago
Paradigm Biopharmaceuticals Advances Phase 3 Osteoarthritis Trial and Expands Pipeline
PremiumCompany Announcements
Paradigm Biopharmaceuticals Advances Phase 3 Osteoarthritis Trial and Expands Pipeline
28d ago
Paradigm Biopharmaceuticals Announces Phase 3 Trial Update Webinar
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Phase 3 Trial Update Webinar
1M ago
Paradigm Biopharmaceuticals Expands ASX Quotation with New Securities
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Expands ASX Quotation with New Securities
1M ago
Paradigm Biopharmaceuticals Secures US$27 Million in Convertible Notes Agreement
Premium
Company Announcements
Paradigm Biopharmaceuticals Secures US$27 Million in Convertible Notes Agreement
2M ago
Paradigm Biopharmaceuticals Issues 7 Million Convertible Notes
Premium
Company Announcements
Paradigm Biopharmaceuticals Issues 7 Million Convertible Notes
2M ago
Paradigm Biopharmaceuticals Completes Share Issuance Under Convertible Securities Agreement
PremiumCompany Announcements
Paradigm Biopharmaceuticals Completes Share Issuance Under Convertible Securities Agreement
2M ago
Paradigm Biopharmaceuticals Announces Quotation of New Securities
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Quotation of New Securities
2M ago
Paradigm Biopharmaceuticals Announces Convertible Notes Issue
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Convertible Notes Issue
2M ago
Paradigm Biopharmaceuticals Announces Proposed Securities Issue
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Proposed Securities Issue
2M ago
Paradigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Study in the US
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Study in the US
2M ago
Paradigm Biopharmaceuticals Expands Osteoarthritis Portfolio with New Acquisition
Premium
Company Announcements
Paradigm Biopharmaceuticals Expands Osteoarthritis Portfolio with New Acquisition
2M ago
Paradigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Trial
Premium
Company Announcements
Paradigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Trial
3M ago
Paradigm Biopharmaceuticals’ General Meeting Results and Future Meeting Plans
PremiumCompany Announcements
Paradigm Biopharmaceuticals’ General Meeting Results and Future Meeting Plans
3M ago
Paradigm Biopharmaceuticals Secures US Ethics Approval for Phase 3 Osteoarthritis Trial
PremiumCompany Announcements
Paradigm Biopharmaceuticals Secures US Ethics Approval for Phase 3 Osteoarthritis Trial
3M ago
Paradigm Biopharmaceuticals Seeks Shareholder Approval for Strategic Resolutions
PremiumCompany Announcements
Paradigm Biopharmaceuticals Seeks Shareholder Approval for Strategic Resolutions
4M ago
Paradigm Biopharmaceuticals Advances Phase 3 Trial for Osteoarthritis Treatment
PremiumCompany Announcements
Paradigm Biopharmaceuticals Advances Phase 3 Trial for Osteoarthritis Treatment
4M ago
Paradigm Biopharmaceuticals to Present at NWR Virtual Healthcare Conference
PremiumCompany AnnouncementsParadigm Biopharmaceuticals to Present at NWR Virtual Healthcare Conference
5M ago
Paradigm Biopharmaceuticals Reports Reduced Losses Amid Ongoing Osteoarthritis Treatment Development
Premium
Company Announcements
Paradigm Biopharmaceuticals Reports Reduced Losses Amid Ongoing Osteoarthritis Treatment Development
6M ago
Paradigm Biopharmaceuticals Secures Ethics Approval for Phase 3 Osteoarthritis Trial
Premium
Company Announcements
Paradigm Biopharmaceuticals Secures Ethics Approval for Phase 3 Osteoarthritis Trial
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >